Apoc3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The APOC3 (Apolipoprotein C-III) gene encodes a component of very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). It plays a key role in regulating plasma triglyceride levels by inhibiting lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. APOC3 is primarily expressed in the liver and, to a lesser extent, in the intestine, where it is synthesized as a preproprotein and secreted as a mature 79-amino acid glycoprotein after signal peptide cleavage. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Symbol | APOC3 | [4]
| Full Name | Apolipoprotein C-III | [5]
| Chromosomal Location | 11q23.3 | [6]
| Aliases | ApoC-III, APOC3 | [7]
| Gene ID | 345 |
| Ensembl ID | ENSG00000110245 |
APOC3 is an 79-amino acid protein that belongs to the apolipoprotein C family. Its structure consists of:
The protein exerts its functions through several mechanisms:
APOC3 expression is tightly regulated at the transcriptional level:
APOC3 has emerged as a significant player in Alzheimer's disease pathophysiology:
The molecular mechanisms by which APOC3 influences disease involve:
| Therapy Type | Example | Status | Mechanism |
|---|---|---|---|
| Antisense Oligonucleotide | Volanesorsen (ISIS 304801) | Approved (EU) | RNase H-mediated mRNA degradation |
| siRNA | Olpasiran (AMG 890) | Phase 2 | RNAi-mediated APOC3 knockdown |
| Monoclonal Antibody | Binding agent | Preclinical | Neutralizes circulating APOC3 |
| Small Molecule | To be developed | Discovery | Inhibit APOC3 production |
Given the role of APOC3 in neurodegeneration:
The study of Apoc3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Zhong et al., 2020. APOC3 in neurodegeneration. 2020. ↩︎
Tall and Rader, 2018. Lipids and brain health. Nat Rev Neurol. 2018. ↩︎
Wang et al., 2015. APOC3 genetic variants and lipid levels. 2015. ↩︎
Lee et al., 2019. APOC3 and Alzheimer's disease risk. 2019. ↩︎
Ginsberg et al., 2018. Volanesorsen and hypertriglyceridemia. 2018. ↩︎
Toth et al., 2020. APOC3 inhibition and cardiovascular outcomes. 2020. ↩︎
Mahley and Rall, 2015. Apolipoproteins and neurodegeneration. Ann Neurol. 2015. ↩︎